Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD)

Lieke E. J. M. Scheepers, Andrea M. Burden, Ilja C. W. Arts, Bart Spaetgens, Patrick Souverein, Frank de Vries*, Annelies Boonen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Web of Science)
10 Downloads (Pure)

Abstract

Objectives. When urate lowering therapy is indicated in patients with gout, medication adherence is essential. This study assesses non-persistence and non-adherence in patients with newly diagnosed gout, and identifies factors associated with poor medication adherence. Methods. A retrospective data analysis was performed within the UK Clinical Practice Research Datalink (1987-2014) among incident gout patients, aged540 years and starting allopurinol (n = 48 280). The proportion of patients non-persistent (a first medication gap of 590 days) after 1 and 5 years, and median time until a first 90-day gap was estimated using Kaplan-Meier statistics in those starting allopurinol and restarting after a first interruption. Non-adherence (proportion of days covered < 80%) over the full observation period was calculated. Multivariable Cox-or logistic regressions assessed factors associated with non-persistence or non-adherence, respectively. Results. Non-persistence increased from 38.5% (95% CI: 38.1, 38.9) to 56.9% (95% CI: 56.4, 57.4) after 1 and 5 years of initiation. Median time until a first 90-day gap was 1029 days (95% CI: 988, 1078) and 61% were non-adherent. After a first gap, 43.3% (95% CI: 42.7, 43.9) restarted therapy within 1 year, yet only 52.3% (95% CI: 51.4, 53.1) persisted for 1 year. Being female and a current smoker increased the risk for non-persistence and non-adherence, while older age, overweight, receiving anti-hypertensive medication or colchicine and suffering from dementia, diabetes or dyslipidaemia decreased the risk. Conclusion. Medication adherence among gout patients starting allopurinol is poor, particularly among females and younger patients and patients with fewer comorbidities. Medication adherence remains low in those reinitiating after a first gap.
Original languageEnglish
Pages (from-to)1641-1650
Number of pages10
JournalRheumatology
Volume57
Issue number9
DOIs
Publication statusPublished - 1 Sep 2018

Keywords

  • gout
  • allopurinol
  • persistence
  • adherence
  • urate lowering therapy (ULT)
  • URATE-LOWERING THERAPIES
  • HEALTH-CARE COSTS
  • GENERAL-PRACTICE
  • SERUM URATE
  • ADMINISTRATIVE CLAIMS
  • PHARMACY RECORDS
  • PREVALENCE
  • POPULATION
  • VALIDATION
  • MANAGEMENT

Cite this